PDS Biotechnology (NASDAQ: PDSB – Get Rating) released quarterly earnings data Wednesday. The company reported ($ 0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($ 0.23) of ($ 0.09), MarketWatch earnings reports. During the same period last year, the company earned ($ 0.14) earnings per share.
Shares of PDSB were up $ 0.73 during Friday’s midday trading, reaching $ 4.56. The stock had a trading volume of 552,690 shares, compared to its average volume of 232,316. The company has a 50 day simple moving average of $ 5.66 and a two hundred day simple moving average of $ 7.26. PDS Biotechnology has a twelve-month low of $ 3.47 and a twelve-month high of $ 17.85.
Several institutional investors and hedge funds have recently increased or decreased their holdings in the business. Vanguard Group Inc. increased its stake in PDS Biotechnology by 7.8% in Q1. Vanguard Group Inc. now owns 1,093,885 shares in the company worth $ 6,771,000 after purchasing an additional 79,025 shares during the period. Renaissance Technologies LLC increased its position in PDS Biotechnology shares by 49.5% in the first quarter. Renaissance Technologies LLC now owns 665,037 shares in the company worth $ 4,117,000 after acquiring another 220,300 shares in the last quarter. BlackRock Inc. increased its position in PDS Biotechnology shares by 1.0% in the first quarter. BlackRock Inc. now owns 435,604 shares in the company worth $ 2,697,000 after acquiring another 4,199 shares in the last quarter. Geode Capital Management LLC increased its position in PDS Biotechnology shares by 13.0% in the fourth quarter. Geode Capital Management LLC now owns 208,117 shares in the company valued at $ 1,685,000 after acquiring an additional 23,873 shares during the last quarter. Finally, Millennium Management LLC acquired a new equity interest in PDS Biotechnology in the fourth quarter valued at approximately $ 743,000. 20.94% of the stock is currently held by hedge funds and other institutional investors.
The PDSB has been the subject of several recent analyst reports. Zacks Investment Research downgraded PDS Biotechnology from a “hold” rating to a “sell” rating in a research report on Friday. Noble Financial reaffirmed a “buy” rating and issued a $ 22.00 price target on PDS Biotechnology shares in a research report Thursday. On Friday, Alliance Global Partners lowered its PDS biotech price target from $ 18.00 to $ 16.00 in a research report. Finally, StockNews.com updated PDS Biotechnology to a “sell” rating in a report on Saturday, April 9. Two analysts rated the stock with a sell rating and six gave the company a buy rating. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $ 17.00.
Information on PDS biotechnology (Get evaluation)
PDS Biotechnology Corporation, a clinical stage biopharmaceutical company, focuses on the development of multifunctional anticancer immunotherapies. Its flagship product is PDS0101 (HPV16), which is in a Phase II clinical trial providing first-line treatment for recurrent / metastatic head and neck cancer, human papillomavirus-associated malignancies, and cancer of the cervix.
Receive news and assessments for PDS biotechnology every day – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Biotech PDS and related companies with MarketBeat.com’s FREE daily newsletter.